ada guidelines dpp4 and glp 1 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Medications for Type 2 Diabetes
Description
Nierenberg AA, Agustini B, Khler-Forsberg O, et al
Glucagon Like Peptide 1 Analogs Market Trends The U.K
Drugs 82(14):14691480
doi: 10.1186/s12933-020-01197-z
By systematically assessing symptoms rather than relying on administrative codes, this study offers a reassuring counterweight to signal-generating registry data
